Methylation-Specific Droplet Digital PCR: Testing a Novel Triage Tool for HrHPV-Positive Women in the Cervical Cancer Screening Program of Northern Portugal

Sofia Salta; José Pedro Sequeira; Bárbara Amorim-Fernandes; João Lobo; Inês Baldaque; Paula Monteiro; Fernando Tavares; Valérie Taly; Rui Henrique; Carmen Jerónimo

doi:10.1002/mco2.70203

MedComm ›› 2025, Vol. 6 ›› Issue (7) : e70203 DOI: 10.1002/mco2.70203

LETTER

Methylation-Specific Droplet Digital PCR: Testing a Novel Triage Tool for HrHPV-Positive Women in the Cervical Cancer Screening Program of Northern Portugal

Author information +

¹. Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. António Bernardino de Almeida, Porto, Portugal

². Doctoral Program in Molecular Pathology and Genetics, ICBAS–School of Medicine and Biomedical Sciences–University of Porto, Rua Jorge Viterbo Ferreira, Porto, Portugal

³. Doctoral Program in Biomedical Sciences, ICBAS–School of Medicine and Biomedical Sciences–University of Porto, Rua Jorge Viterbo Ferreira, Porto, Portugal

⁴. Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. António Bernardino de Almeida, Porto, Portugal

⁵. Department of Pathology and Molecular Immunology, ICBAS–School of Medicine and Biomedical Sciences–University of Porto, Rua Jorge Viterbo Ferreira, Porto, Portugal

⁶. Department of Pathology and Laboratory Medicine, Clinical Pathology Service, Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. António Bernardino de Almeida, Porto, Portugal

⁷. Departamento de Estudos e Planeamento, Coordenação Nacional dos Programas de Rastreio de Base Populacional (CN-Rast_Pop), Direção Executiva do Serviço Nacional de Saúde, Alameda Professor Hernâni Monteiro, Portaria B, Porto, Portugal

⁸. Centre de recherche des cordeliers, INSERM, Sorbonne Université, Université de Paris Cité, Équipe 26, Équipe labellisée ligue nationale contre le cancer, Paris, France

henrique@ipoporto.min-saude.pt

carmenjeronimo@ipoporto.min-saude.pt

Show less

History +

PDF

Keywords

cervical cancer screening / colposcopy referral / DNA methylation / HPV-positive women referral / triage

Cite this article

Download citation ▾

Sofia Salta, José Pedro Sequeira, Bárbara Amorim-Fernandes, João Lobo, Inês Baldaque, Paula Monteiro, Fernando Tavares, Valérie Taly, Rui Henrique, Carmen Jerónimo. Methylation-Specific Droplet Digital PCR: Testing a Novel Triage Tool for HrHPV-Positive Women in the Cervical Cancer Screening Program of Northern Portugal. MedComm, 2025, 6(7): e70203 DOI:10.1002/mco2.70203

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	P. J. Maver and M. Poljak, “Primary HPV-Based Cervical Cancer Screening in Europe: Implementation Status, Challenges, and Future Plans,” Clinical Microbiology and Infection 26, no. 5 (2020): 579-583.

[2]	S. Salta, J. P. Sequeira, J. Lobo, et al., “Preliminary Outcomes of the Cervical Cancer Screening Program of Northern Portugal: A Snapshot,” Journal of Infection and Public Health 17, no. 6 (2024): 1057-1064.

[3]	S. Salta, J. Lobo, B. Magalhães, R. Henrique, and C. Jerónimo, “DNA Methylation as a Triage Marker for Colposcopy Referral in HPV-Based Cervical Cancer Screening: A Systematic Review and Meta-Analysis,” Clinical Epigenetics 15, no. 1 (2023): 125.

[4]	H. Kelly, Y. Benavente, M. A. Pavon, S. De Sanjose, P. Mayaud, and A. T. Lorincz, “Performance of DNA Methylation Assays for Detection of High-Grade Cervical Intraepithelial Neoplasia (CIN2⁺): A Systematic Review and Meta-Analysis,” British Journal of Cancer 121, no. 11 (2019): 954-965.

[5]	S. Salta, L. Maia-Moco, H. Estevao-Pereira, et al., “Performance of DNA Methylation-Based Biomarkers in the Cervical Cancer Screening Program of Northern Portugal: A Feasibility Study,” International Journal of Cancer Journal International Du Cancer 149, no. 11 (2021): 1916-1925.

[6]	M. Demarco, N. Hyun, O. Carter-Pokras, et al., “A Study of Type-Specific HPV Natural History and Implications for Contemporary Cervical Cancer Screening Programs,” EClinicalMedicine 22 (2020): 100293.

[7]	A. Rosário, A. Sousa, J. Marinho-Dias, et al., “Impact of High-Risk Human Papillomavirus Genotyping in Cervical Disease in the Northern Region of Portugal: Real-World Data From Regional Cervical Cancer Screening Program,” Journal of Medical Virology 95, no. 1 (2023): e28414.

[8]	J. P. Sequeira, J. Lobo, V. Constâncio, et al., “DigiMir Test: Establishing a Novel Pipeline for MiR-371a Quantification Using Droplet Digital PCR in Liquid Biopsies from Testicular Germ Cell Tumor Patients,” Frontiers in Oncology 12 (2022): 876732.

[9]	S. Dick, W. W. Kremer, L. M. A. De Strooper, et al., “Long-Term CIN3⁺ Risk of HPV Positive Women After Triage With FAM19A4/miR124-2 Methylation Analysis,” Gynecologic Oncology 154, no. 2 (2019): 368-373.

[10]	V. M. Verhoef, D. A. Heideman, F. J. van Kemenade, et al., “Methylation Marker Analysis and HPV16/18 Genotyping in High-Risk HPV Positive Self-Sampled Specimens to Identify Women With High Grade CIN or Cervical Cancer,” Gynecologic Oncology 135, no. 1 (2014): 58-63.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.